

A man with a beard and glasses, wearing a blue and white JDRF tank top, is shown from the chest up, looking upwards and to the left. The tank top features the JDRF logo and the text 'IMPROVING LIVES. CURING TYPE 1 DIABETES.' and 'RUN TO CURE DIABETES'. The background is a clear blue sky.

# 2022 Our Impact

# Contents

Foreword from our Chief Executive	03
Our impact in numbers	04
Our strategy	05
Goal 1: Drive research to cure, treat and prevent type 1	06
Goal 2: Accelerate access to type 1 technologies and medicines	12
Goal 3: Support people living with type 1	16
Fundraising activity and campaigns	24
Thank you	26

Cover image: Seun Alaba, JDRF supporter



Mary Murphy, Community Events Officer at JDRF

“From campaign success increasing access to life-changing treatments to paving the way for ground-breaking research in the UK and beyond, JDRF has been at the forefront.”

Karen Addington  
Chief Executive Officer



# Foreword from our Chief Executive

2022 has been a year of unprecedented change. We fundamentally improved the lives of people living with type 1 diabetes. From campaign success increasing access to life-changing treatments to paving the way for ground-breaking research in the UK and beyond, JDRF has been at the forefront. None of this would be possible without the generosity and loyalty of our supporters – thank you.

We launched the **Type 1 Diabetes Grand Challenge**, made possible through the largest ever single philanthropic gift from Steve and Sally Morgan and their charitable foundation. Our partnership with Diabetes UK and the Steve Morgan Foundation has driven at pace a programme of ground-breaking research into beta cells, novel insulins and immunological treatments like never before. We also expanded the **ELSA study** to screen children aged 3-13 across the UK for type 1 diabetes.

Through our **policy work** and in collaboration with NHS England and Professor Partha Kar, we achieved a significant breakthrough to ensure that everyone with type 1 diabetes in the UK will be offered flash or continuous glucose monitoring technology free on the NHS in England and Wales.



We were instrumental in **widening access to closed loop systems** for all people with type 1 in Scotland. We also helped to **focus policy makers on eating disorders in type 1 diabetes** with a new inquiry headed by Sir George Howarth MP and Rt. Hon Theresa May MP.

On an international level, thanks to your support and JDRF funded research, **teplizumab was approved in the US**, paving the way for its approval in the UK. This drug has the power to alter the course of type 1 diabetes and delay its onset.

We launched the **Global T1D Index**, a first-of-its-kind index which will raise awareness of the unmet need of people living with type 1 diabetes globally. We held our annual **Mission Summit** in England for the first time, bringing together award-winning scientists from around the world with industry partners, international donors, and key opinion leaders.

We are so grateful to you, our supporters, who should take pride in all the achievements you have enabled in 2022. We were thrilled to be able to be with you again in person; our flagship **One Walk** and the **London Ball** were shining examples of what happens when we bring our community together.

Despite the challenges of the past three years, it's through your generous support and commitment, along with the tireless work of our volunteers, staff and Board that we have maintained our focus and made incredible progress towards our mission in 2022.

**We could not do it without you.**



**Karen Addington**  
**Chief Executive Officer**

## Our impact in numbers



**£1,940,000**  
raised for UK research projects



**800,000**  
visits to the JDRF website



**800+**  
attendees at our community events



# Our Strategy

We're in the second year of our bold three-year strategy and have made significant progress towards our vision of a world without type 1 diabetes. With our incredible supporters, we've been able to advance major breakthroughs in research, transformed access to life-changing technology and expanded our reach to support more people.

It's this commitment from our funders that's enabled us to make these significant leaps in 2022. By helping us push the boundaries in our understanding of type 1, together we're paving the way for future cures that are closer than ever before.

Pete Davies, JDRF supporter



## GOAL 1

Drive research to cure, treat and prevent type 1



## GOAL 2

Accelerate access to type 1 treatment technologies and medicines




## GOAL 3

Support people living with type 1



2022 was a year of innovation.

Our research breakthroughs included the first treatment to delay type 1, a new screening trial to identify children at risk and the largest ever single investment in type 1 research in the UK. Real results with real world impacts.





# Goal 1

## Drive research to cure, treat and prevent type 1

**We continue to drive towards achieving our ultimate goal: finding cures for type 1. Until that time and only with your support, we strive to bring treatments to people living with the condition that improve lives today.**



**£50,000,000**

**via the Steve Morgan Foundation**

### **TOGETHER, OUR BREAKTHROUGHS WILL FIND A CURE**

Our partnerships with researchers, scientists and other organisations across the globe underpin our research success. Working towards the same goal and pooling our resources means we're able to bring together the best people, techniques and institutions to maximise our impact.

This past year we built one of our most significant partnerships, the Type 1 Diabetes Grand Challenge, which has the potential to change the face of type 1 diabetes research in the UK and globally. Another fundamental partnership is, of course, the one we have with our supporters. Your donations are vital for us to be able to forge such monumental relationships.

### **Steve Morgan Foundation**

In 2022, we secured the largest ever single gift for type 1 research in the UK. The landmark £50 million Type 1 Diabetes Grand Challenge was made possible by the generosity of our donors Steve and Sally Morgan through the Steve Morgan Foundation.

This project will fund large innovative research projects, bringing together the world's best scientists over the next five years. It will

Katie Partridge, researcher at University of Exeter





**£1,000,000**

**in partnership with the  
Lorna and Yuti  
Chernajovsky  
Biomedical Foundation**

focus on three vital areas of type 1 research, including new types of insulin, creating new beta cells and stopping the immune attack from taking place.


We've appointed 17 leading international scientists to help identify the projects with the most promise. This partnership with Diabetes UK and the Steve Morgan Foundation is an unprecedented opportunity to progress research and treatments.

## **Connect Immune Research**

Under our leadership, the Connect Immune Research partnership is researching the common causes between autoimmune conditions. This will lead to an increase in the development of treatments which target multiple conditions.

This year, we've secured nearly £1 million in a partnership with the Lorna and Yuti Chernajovsky Biomedical Foundation. This has funded 10 projects in autoimmunity, bringing together different research teams.


We've also welcomed two charities to the partnership, the British Thyroid Foundation and the Royal Free Charity. Working collaboratively means we'll find the treatments and cures we need much faster.



Professor Lucy Walker, researcher at UCL

“The world now has a drug which is proven to tackle the root causes of type 1 diabetes effectively, delaying the onset of the condition and slowing down disease progression.”

**Karen Addington**  
CEO of JDRF UK



## A world first for treatment to delay type 1

Teplizumab, an immunotherapy drug, can delay type 1 by up to three years was approved for use in the US. The drug tackles the root cause of the condition and has the potential to slow progression of type 1 in the long-term.

JDRF has been instrumental in the development of teplizumab and funded the exploratory research nearly thirty years ago. Now, the USA's Food and Drug Administration has approved it for people who don't have type 1 but are at high risk of developing the condition. This represents an extraordinary turning point that could pave the way for its use in the UK.

Delaying the onset of type 1 diabetes makes a huge difference as it can protect people from long-term complications. For children, this delay means their pancreas can grow, reducing the burden of managing their condition.

Teplizumab can also help prevent traumatic and potentially fatal diabetic ketoacidosis (DKA), a severe lack of insulin.

“This drug can buy precious time whilst the search for a cure is ongoing – a hopeful reality in our lifetime. My son Peter never had this opportunity. To have teplizumab licensed in the UK will be a giant step forward.”

**Beth Baldwin**, whose son Peter died of diabetic ketoacidosis (DKA) aged 13

## Screening children for type 1

We're co-funding a new screening trial that could transform the way type 1 is identified and managed in its earliest stages. The Early Surveillance for Autoimmune diabetes project (ELSA) is the first of its kind in the UK to identify children aged 3-13 who are at high risk of developing type 1.

We're laying the groundwork for the development of a transformational UK-wide screening programme. This project will provide crucial insights into practical and effective ways to screen large numbers of children in the UK. Detection of children at risk is an opportunity to provide support and information earlier. It may help to avoid traumatic diagnosis situations such as developing diabetic ketoacidosis (DKA).

The Early Surveillance for Autoimmune diabetes project (ELSA) is the first of its kind in the UK to identify children aged 3-13 who are at high risk of developing type 1.

## Funding the next generation of researchers

Together with the UK Medical Research Council, we funded our first Clinical Research Training Fellowship. We're supporting Daniel Doherty to complete his PhD focusing on improving islet transplants, where cells from the pancreas of a donor are implanted into the liver of a person with type 1.

The islets of Langerhans, known as 'islets' for short, are a part of the pancreas in which the insulin-producing beta cells are located. Islet transplants can help people with type 1 who struggle with their glucose control, but they are far from perfect. Daniel's goal is for islet transplants to work better so they can help more people with type 1 diabetes.





# JDRF IN THE MEDIA

## Telling our story

- The launch of the Type 1 Diabetes Grand Challenge secured features with **BBC Breakfast, Sky News, the Mirror** and extensive press and regional media.
- We secured coverage in **The Guardian** supplement for Diabetes Awareness Week on **myths and misconceptions about type 1 diabetes**.
- **BBC Breakfast, BBC News, Radio 4's Today programme** and many other national media outlets covered the news that the ELSA study has expanded to screen children aged 3-13 across the UK for type 1 diabetes
- We raised awareness of the FDA's approval of the drug teplizumab. This resulted in widespread national media coverage including: a podcast with **The Economist, BBC News, Sky News, The Times, The BMJ**, and **Daily Mail**.

## Funding world-class research

JDRF-funded researcher, Professor Maïke Sander, won the prestigious Albert Renold Prize at the European Association for the Study of Diabetes conference. Her outstanding work is studying a group of cells called pancreatic islets, where insulin-producing beta cells are found.

Out of the 16 prizes awarded at the conference, 13 have gone to researchers we've funded during their careers. This shows that we fund the best internationally recognised professionals.



We work with governments, decision-makers and the NHS to make sure that the latest treatments and innovations get to the people who need them. By advocating for change, we're shaping policy across the UK for a better future for everyone affected by type 1 diabetes.

Berni Warren, JDRF supporter who lives with type 1 and a visual impairment



## Goal 2 Accelerate access to type 1 technologies and medicines

“In March we were delighted with the positive news that everyone with type 1 diabetes in England and Wales will now have access to either flash glucose monitoring or continuous glucose monitor (CGM) technology free on the NHS.”

### IMPROVING ACCESS TO TECHNOLOGY ON THE NHS

In March we were delighted with the positive news that everyone with type 1 diabetes in England and Wales will now have access to either flash glucose monitoring or continuous glucose monitor (CGM) technology free on the NHS.

Our long-term policy work played a pivotal role in changing regulatory guidance. The National Institute for Health and Care Excellence (NICE) incorporated our recommendations in their guidance to ensure more people benefit from this life-changing technology. It signifies the most significant change to treatment since home blood glucose monitoring was introduced more than forty years ago.

Access to such digital health technology will help prevent life threatening blood glucose fluctuations and reduce the long-term risk of diabetes-related complications, including kidney failure and sight loss. This will, in turn, help alleviate the mental burden of this relentless condition.

The new national guidelines will substantially reduce health inequalities and improve long term outcomes for people with type 1 diabetes. We're now working to make sure that all local NHS health commissioning boards follow this guidance.



## Scotland approved hybrid closed loop

Hybrid closed loop (HCL), also known as the artificial pancreas, is a proven treatment at the frontier of health technology. HCL automates many of the constant decisions people with type 1 make by using an advanced algorithm which links insulin pumps to continuous glucose monitors.

HCL has been developed thanks to rigorous international JDRF-funded research and clinical trials over almost 20 years. With your support, we've not only funded the research, we've also campaigned to make it available to those who can benefit from it.

In 2022, our policy work was key to widening access to closed-loop systems for all people with type 1 diabetes in Scotland. We provided clinically proven evidence about the ability of HCL to transform the lives of people with type 1 to the Scottish Health Technologies Group, who advise NHS Scotland.

Our evidence was taken on board and the ground-breaking technology is now being rolled out in Scotland, enabling thousands more people to live



longer, healthier lives, by reducing the risks of complications including heart failure, loss of limbs, kidney failure and sight loss.

Just a few years ago, we could only speak about hybrid closed loop systems in terms of research. We're delighted it's now on the cusp of getting into the hands of people who need it the most in Scotland.

Our campaigning work now looks towards England, Wales and Northern Ireland as we endeavour to put the UK in the vanguard of countries making HCL available at the point of need.

“People with type 1 diabetes who already use closed loop systems consistently tell JDRF about its massive impact on improving their wellbeing, so it was crucial that our evidence highlighted the quality of life and mental health benefits of this technology.”

**Rachael Chrisp**, Head of Policy and Public Affairs at JDRF


## YASMIN'S STORY

Through our research and advocacy work, we champion technology that has the ability to relieve much of the burden of managing type 1 day in and day out, and campaign for it to be made available to all who need it.

Yasmin Hopkins was diagnosed with type 1 diabetes when she was 11 years old. She took part in a pilot project to trial an HCL

system to help her manage her blood glucose levels.

"I took part in a pilot at my local hospital for a hybrid closed loop. From day one it was amazing. Before, I would experience a lot of highs, which I'd then overcorrect, go low and then eat a lot of sugar. All of that was eradicated."



## Type 1 and Disordered Eating Parliamentary Inquiry

As type 1 diabetes and food are closely linked, people with type 1 are at an increased risk of developing what's known as disordered eating or an eating disorder. With a focus on food, weight and blood glucose, it can lead some people to restrict their insulin in order to lose weight.

In June, a Parliamentary inquiry into type 1 diabetes and disordered eating (T1DE) was launched. This inquiry has the aim of setting recommendations for the NHS, international research programmes and the wider healthcare system to have more informed evidence and be better equipped to prevent and treat the complexities of living with an eating disorder and type 1.

Sir George Howarth MP and Rt. Hon Theresa May MP are co-chairing this important inquiry and JDRF is the secretariat and will be writing the parliamentary report. The inquiry is hearing from experts in academia, the NHS, the charity sector, international researchers and those with lived experience of T1DE to help shape a report to better understand the condition and make recommendations to improve treatment and care.





Throughout 2022, we continued to provide vital support and information for people with type 1. We're here to offer reassurance and support to thousands of people living day to day with type 1.





# Goal 3

## Support people living with type 1

From answering individual enquiries to hosting events and providing trusted resources, we support people with type 1 and their families every day. That's why we continued to widen and deepen our engagement with more diverse type 1 audiences across multiple demographics.

### **TYPE 1 AND DISORDERED EATING HUB (T1DE)**

We raised awareness and provided information for people living with type 1 diabetes and eating disorders by developing a new hub on our website. It contains lots of helpful content on risk factors, symptoms and important signposting, alongside videos of people with lived experience of the issue.

We also worked on getting the issue into the mainstream and advised scriptwriters from Coronation Street on a T1DE storyline to ensure accuracy and sensitivity.

Together with the University Hospital Dorset Trust, we hosted the fourth national T1DE conference. It provided a unique opportunity for healthcare professionals to learn about emerging good practice to help integrate services and develop interventions for people experiencing type 1 diabetes and eating disorders.

We want to raise awareness of T1DE with healthcare professionals to help provide stronger support for people living with type 1 who experience this complex and isolating condition.

Joe Lewis, who lives with type 1, and his partner

## The Six Principles of Good Peer Support

Having someone who understands what you're going through when living with type 1 can make a huge difference. Support from other people experiencing type 1, called peer support, can help people learn to manage their condition.

We worked collaboratively with Diabetes UK, NHS England and people with lived experience, to produce The Six Principles of Good Peer Support for People Living with Type 1 Diabetes,

These principles are intended to demonstrate to both clinicians and potential group members what they should expect from a peer support group and their benefits.

It also gives clinicians the confidence to refer people with type 1 to support groups and provides a helpful framework for those involved in peer support to embed consistent and clear values.

Seun Alaba, who lives with type 1, and his partner



“This piece of work, led by six amazing individuals living with type 1 diabetes, is a welcome step forward and hopefully sets the template for peer support being as much a fundamental part of type 1 diabetes care as education and technology.”

**Professor Partha Kar**, National Specialty Advisor for Diabetes at NHS England

## Supporting children and young people

Living with diabetes can be an overwhelming experience for children and young people. As many as 6 in 10 experience what is known as severe diabetes distress, where their mental health is affected. If untreated, it can lead to depression and even post-traumatic stress disorder.

With few specialist paediatric diabetes psychologists, many children and young people don't get the support they desperately need.

To combat this, we teamed up with DigiBete to provide children, young people and their families with the information and support they need to live well with type 1 diabetes.

Funded by NHS England, DigiBete is a video platform and app designed to specifically help young people and families manage type 1 diabetes. The app enables young people and their families to store insulin ratios, doses and pump settings. It contains videos and information co-created with children and clinically approved by specialist type 1 psychologists on a range of topics. It's currently used by 60% of families and young people in England, supporting them at a crucial time in their lives.

This exciting new collaboration will enable JDRF and DigiBete to strengthen digital resources and co-create information about a broad range of subjects from daily management to nutrition and wellbeing. This collaboration will also encourage more young people to become involved in type 1 research and advocacy work, helping them to shape future treatments, as well as local and national healthcare services, in a way that benefits everyone living with type 1.

We're grateful to one of our Accelerator Programme families for their significant donation which made this innovation possible. They had a personal connection to the issue and asked if we could explore the viability of digital resources to adolescents who feel they experience psychological trauma because of type 1 diabetes.



**6 in 10**

**experience severe  
diabetes distress**

Alfie, whose family are JDRF  
supporters



## Community engagement in numbers

**13,400**

families supported with newly diagnosed resources

**5,600**

adults supported with newly diagnosed resources

**5,494**

KIDSACs distributed to support newly diagnosed young people

## Youth Ambassador Programme

We refreshed our Youth Ambassador Programme which empowers young people living with type 1 to share their experiences of managing their condition with others. Since launch, over 200 Youth Ambassadors have registered to take part in the programme.

**46,000**

support resources given to people with type 1 and healthcare professionals

**25,200**

people accessed our schools e-learning module

**3,400**

registrations for our events

**JDRF** IMPROVING LIVES. CURING TYPE 1 DIABETES.

**13**

community events held throughout the UK



## Global type 1 index

We launched the first Type 1 Diabetes Index, a tool that measures the global impact of type 1 diabetes in every country around the world.

Type 1 has never been measured in this way or at this scale. The T1D Index and accompanying research, published by the Lancet Diabetes and Endocrinology, will be used to identify key interventions that could change the current trajectory for type 1 diabetes. It will find out how we can reduce the impact

on people around the world and ultimately, save lives.

The index will give us the evidence we need to urgently demand greater access to treatments for people with type 1, no matter where in the world they live.

“Type 1 has never been measured in this way or at this scale.”



### Globally

**From** hundreds of thousands of injections and tests

**To** choosing what to do with 2,252 extra days

**Change the numbers.**  
**Change the story**

Learn more at [T1DIndex.org](https://T1DIndex.org)



## CADEN'S STORY

Receiving a type 1 diagnosis for a child can be a traumatic and difficult experience for the entire family. Our free KIDSAC helps parents and their child to deal with their diagnosis and manage their child's condition better. Along with information leaflets, it also contains Rufus, the bear with type 1 diabetes with felt patches on his test and injection sites.

Four-year-old Caden lives with Down's syndrome and type 1 diabetes. His sister Jamieleigh tells us how Rufus gave him comfort during the hard days in hospital.

*"We didn't realise how life-changing type 1 is, but we had to quickly accept it. Caden was given Rufus the bear from JDRF in hospital when he was starting to feel a bit better. He really bonded with Rufus, and they became best friends instantly."*

**Jamieleigh**, Caden's sister





## Our fundraising activity and campaigns

Amidst a backdrop of economic uncertainty, we continued to deliver campaigns and events which raise vital funds to drive our research forwards.

### Corporate Partnerships

We rely on significant funding from our corporate partners to help us deliver our mission goals. One example we're very grateful for is the Peter Cooper Motor Group in Southampton, a long-term supporter of JDRF, who raised £20,000 for us during their 40th anniversary year through a range of fundraising activities with their staff and customers.

### Major Giving

We are grateful to our Patrons and members of our Accelerator Programme who drive our global movement to improve, transform and eradicate type 1 diabetes through their major gifts. Throughout 2022, these incredible donors invested more than £1 million, enabling us to bring new opportunities to the type 1 research community, as well as sustaining our existing programme of projects and awards.

“Being a Patron gives me the opportunity to become more involved. It's more than just signing a cheque; it's understanding what's being done with the money. I am tremendously proud of what we have achieved so far.”

**Dominic**



**£1,000,000**

**of donations from our Patrons and members of our Accelerator Programme**

## #WeAreOne Campaign

On World Diabetes Day, we launched our awareness and fundraising campaign which celebrated the power of our type 1 community. Our appeal brought our community together under the banner #WeAreOne and showed that by coming together, we raise more awareness and more money to fund research than we do alone.

Our campaign resonated with our supporters and community and raised over £67,000, with 800 supporters joining our Facebook group and engaging with us on social media.

“What I didn’t know back then was that I’d meet strangers like you who’d support me through the ups and the downs. That we’d rally together on days like World Diabetes Day to celebrate the progress we’ve made and share our excitement at where research is taking us. That by supporting research, we hold the power to change the future for all of us – because #WeAreOne.”

**Laura**, whose daughter Lottie was diagnosed with type 1 just before her fourth birthday

Over **10,000** people donated to JDRF, including **4,000** first time donors.



Over **2,000** people played the lottery with JDRF in 2022.

**84** JDRF supporters won a cash prize including three lucky winners who won **£1,000** each.

**738** people organised a fundraiser for JDRF, raising **£346,943** in 2022

**1500** participants in our fundraising events



## One Walk

We were thrilled to relaunch our flagship **One Walk** series in person for the first time since the start of the pandemic. We were so grateful to see the type 1 community come together to walk and raise funds for a cure. Held in London, St. Andrews, Manchester and Cardiff, the events raised over **£130,000** with **940 people** joining us.



## Cycle for a Cure

Over **300 supporters** cycled between **100 and 400 miles** throughout May, with 100 miles marking 100 years of insulin and 400 miles for the 400,000 people living with type 1 in the UK. Although this was a virtual event, we achieved our targets and our dedicated supporters raised over **£150,000**.



## London Marathon

The 2022 marathon was postponed from April until October to ensure it could be held safely during the COVID-19 pandemic. Nevertheless, we had over **170 runners** take part – of whom 56 had type 1 diabetes – and raised over **£383,000**. Thank you to all our supporters and volunteers who cheered on the runners and organised the supporter zones and recovery venue.



### JDRF in the media: World Diabetes Day

- Our global ambassador, cellist **Sheku Kanneh-Mason**, sported his #WeAreOne badge on **BBC Breakfast**.
- Actor **James Norton** used his reach to talk about type 1 technology with his social media followers.



# Thank you

“Our supporters are the lifeblood of our organisation. Our ability to improve the lives of people with type 1 and make incredible progress towards finding cures has only been possible through your generous support. There are so many people that give their time, energy and money. On behalf of all of us at JDRF, a heartfelt thank you for your ongoing support – we can’t thank you enough.”

**Terence Lovell**, Fundraising and Engagement Director at JDRF

## OUR ACCELERATOR PROGRAMME MEMBERS

- Dominic Christian and Kate Birch
- Lincoln Benet
- The Claringbull Family
- Niall Curran and Sue Reid
- Rosemary, Gordon and Cameron Fuller
- The Haywood Family
- Patrick and Jane Kennedy
- Wilson Leech
- The Manktelow Family
- The Rt Hon Theresa May MP
- The Pardoe Family
- The Sethia Family
- The Wilkinson Family
- The Zhao Family

## CORPORATES

- Abbott Diabetes Care UK
- Dexcom UK Distribution Ltd
- Insulet International Ltd
- Roche Diabetes Care UK
- Lilly UK
- Novo Nordisk Ltd
- Sanofi UK
- Air Liquide Healthcare Ltd
- Medtronic Ltd
- Medtrum Ltd
- Menarini Diagnostics Ltd
- Dextro Energy GmbH
- The Syncona Foundation
- Ford Motor Company Ltd
- Peter Cooper Motor Group
- Hoban Waste Management
- Nelsons

**With special  
thanks to Steve and  
Sally Morgan of  
The Steve Morgan  
Foundation**

And thank you to all our Patrons for their generous investment in our work:  
**[www.jdrf.org.uk/philanthropy](http://www.jdrf.org.uk/philanthropy)**

## TRUSTS

- Coldstones Charitable Trust
- The Elizabeth and Prince Zaiger Trust
- Hans and Julia Rausing Trust
- Hummingbird Charitable Trust
- Nimar Charitable Trust
- Peter Harrison Foundation
- PF Charitable Trust
- Robert Barr's Charitable Trust
- Robert Luff Foundation Limited
- The R S Macdonald Charitable Trust
- Worshipful Company of Spectacle Makers

## VOLUNTEERS

Volunteers play a vital role and in 2022, over 500 people volunteered to support us. We're grateful to all our dedicated supporters. Our Board Directors and advisors from the scientific community freely give their time and are an important part of our team.

### Our volunteer panel

We launched our Insight and Experience Panel of 140 people with lived experience of type 1 to support our work. The panel assisted with providing lived experience for NICE consultation responses. It supports discussions about providing insight to international initiatives and building consensus on Patient Reported Outcomes among the international research community.



**In 2022, we saw unprecedented progress in accelerating life-changing breakthroughs to cure, prevent and treat type 1 diabetes and its complications. This momentum is only possible thanks to your enduring commitment as supporters. Your passion means we can be even more ambitious in our plans for 2023 and beyond.**

We work with a range of dedicated corporate partners, trusts, foundations and philanthropists, and offer multiple opportunities to get involved in supporting type 1 diabetes research. To find out how you can help, please contact us on:

**[supportercare@jdrf.org.uk](mailto:supportercare@jdrf.org.uk)**

*We are JDRF, the leading global type 1 diabetes charity.*

*We fund world-class research, support the type 1 community and campaign for broader NHS provision of treatments and technologies.*

*Our reach extends around the globe – we work with the best researchers in the world to prevent, treat and cure type 1.*



#### **CONTACT DETAILS**

**Address:** JDRF, Angel Gate, 17/18, City Road, London, EC1V 2PT  
**Telephone:** 020 7713 2030

Copyright © 2023 | Juvenile Diabetes Research Foundation Ltd (JDRF) is a charity registered in England and Wales (No. 295716) and in Scotland (No. SC040123). Registered address: 17/18 Angel Gate, City Road, London EC1V 2PT. Tel: 020 7713 2030 Registered as a company limited by guarantee, in England and Wales (No 2071638).

